Ellis Andrea
SEC Form 4 insider trading activity
Ellis Andrea has filed 3 SEC Form 4 filings (5 transaction rows) across 1 company, with disclosures dating back to 2026. 3 of those filings fall inside the rolling window. Most recent filing: Jul 13, 2026.
On the most recent filing, Ellis Andrea is listed as Director at BridgeBio Pharma, Inc. Inside the rolling window, Ellis Andrea reported no open-market purchases and 2 open-market sales totaling $5.7M in BBIO. The largest disclosed transaction in the window is a sale of 64,921 BBIO shares on Mar 4, 2026, worth $4.2M.
Companies traded
Other insiders at BBIO
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$5.7M
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Ellis Andrea made?
Ellis Andrea has filed 3 SEC Form 4 filings (5 transaction rows) across 1 company since 2026.
Which companies does Ellis Andrea trade?
Ellis Andrea has filed SEC Form 4 disclosures for 1 company, including BBIO.
When was Ellis Andrea's most recent SEC Form 4 filing?
Ellis Andrea's most recent SEC Form 4 filing on Tracefour is dated Jul 13, 2026.
What is Ellis Andrea's total buy and sell value in the current window?
Inside the rolling retention window, Ellis Andrea bought $0 and sold $5.7M based on SEC Form 4 filings.
What was Ellis Andrea's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 64,921 BBIO shares on 2026-03-04, worth $4.2M, per SEC Form 4 filings.